Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

BACKGROUND. Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Because this is a new target, it is clinically important to understand palbociclib’s safety pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Verma, Sunil, Bartlett, Cynthia Huang, Schnell, Patrick, DeMichele, Angela M., Loi, Sherene, Ro, Jungsil, Colleoni, Marco, Iwata, Hiroji, Harbeck, Nadia, Cristofanilli, Massimo, Zhang, Ke, Thiele, Alexandra, Turner, Nicholas C., Rugo, Hope S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2016
Schlagworte:
Breast Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5061543/
https://ncbi.nlm.nih.gov/pubmed/27368881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0097
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge